Alteogen announced on June 9 that its recombinant human hyaluronidase, ALT-B4, has received a patent grant decision from the European Patent Office (EPO). The company plans to proceed with the necessary steps to complete the patent registration across various European countries.
With this patent registration, Alteogen secures exclusive rights to ALT-B4 in Europe. The company has been actively pursuing patent applications and registrations for ALT-B4 in major markets, including the United States and Europe.
ALT-B4 is a key substance in the subcutaneous (SC) injection formulation change platform. Alteogen developed this substance using domain swapping technology. Currently, global pharmaceutical companies such as MSD, AstraZeneca, GSK, and Biogen are developing SC formulation therapeutics utilizing ALT-B4 under licensing agreements.
The first commercial product based on ALT-B4 is MSD's 'Keytruda SC,' which is sold in the United States under the name 'Keytruda Qle.' This product is considered the first successful case of commercializing the ALT-B4 platform.
ALT-B4 has also been granted a substance patent in the United States, ensuring exclusive rights until 2043. The company plans to strengthen its intellectual property protection through a portfolio that includes patents for formulations and dosages.
Chun Tae-yeon, CEO of Alteogen, stated, "Results are becoming visible in major therapeutic markets such as the United States and Europe," and added, "We will strengthen our global partnerships and commercialization foundations."
In January, Alteogen signed a $285 million contract with GSK subsidiary Tesaro for the development of the SC formulation of the immuno-oncology drug 'Zempare.' In March, the company entered into a $579 million agreement with Biogen to develop two therapeutic products in SC formulation.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.